(3Z)-3-[2-(2,4-Dichlorophenyl)hydrazin-1-ylidene]-1-phenyl-2,3-dihydro-1H-indol-2-one

Catalog No. :
ACCEKR507
CAS No. :
320422-15-9
Molecular Formula :
C20H13Cl2N3O
Molecular Weight :
382.25

IUPAC Name:(Z)-3-(2-(2,4-dichlorophenyl)hydrazineylidene)-1-phenylindolin-2-one

(3Z)-3-[2-(2,4-Dichlorophenyl)hydrazin-1-ylidene]-1-phenyl-2,3-dihydro-1H-indol-2-one structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g90%$555.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(3Z)-3-[2-(2,4-Dichlorophenyl)hydrazin-1-ylidene]-1-phenyl-2,3-dihydro-1H-indol-2-one
IUPAC Name(Z)-3-(2-(2,4-dichlorophenyl)hydrazineylidene)-1-phenylindolin-2-one
MDL No.MFCD00975849
Molecular FormulaC20H13Cl2N3O
Molecular Weight382.25
SMILESO=C1/C(=N\NC2=CC=C(Cl)C=C2Cl)C2=C(C=CC=C2)N1C1=CC=CC=C1
InChI KeyFPTCDKXYQLWIGU-CLCOLTQESA-N
Synonym1-PHENYL-1H-INDOLE-2,3-DIONE 3-[N-(2,4-DICHLOROPHENYL)HYDRAZONE];1H-Indole-2,3-dione, 1-phenyl-, 3-[2-(2,4-dichlorophenyl)hydrazone]
CAS No.320422-15-9

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P280-P301+P312-P302+P352-P305+P351+P338

Synthetic Route by SureRoute

1. ACCEKR507 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACDJTL894 route compound structure diagram
    ACDJTL8945446-18-4 In Stock
  2. Plus
  3. ACTMBP643 route compound structure diagram
    ACTMBP643723-89-7 In Stock
  4. Then
  5. ACCEKR507 route product structure diagram
    ACCEKR507320422-15-9
Inquiry

2. ACCEKR507 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACCPZB630 route compound structure diagram
    ACCPZB630591-50-4 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACCEKR507 route product structure diagram
    ACCEKR507320422-15-9
Inquiry

Comments (0)